ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

ANAB AnaptysBio Inc

26.58
0.24 (0.91%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
AnaptysBio Inc ANAB NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.24 0.91% 26.58 15:33:53
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
26.76 25.64 27.02 26.58 26.34
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
24/4/202408:00PRNUSActym Therapeutics Appoints Thomas Smart as CEO
11/3/202415:41EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/3/202415:36EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11/3/202415:19EDGAR2Form 8-K - Current report
29/2/202408:15GLOBEAnaptys to Present at TD Cowen’s 44th Annual Health Care..
14/2/202409:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202407:35EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202408:15GLOBEAnaptys to Present at Guggenheim’s 6th Annual Biotechnology..
09/1/202418:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202418:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202416:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202416:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:09EDGAR2Form 8-K - Current report
27/11/202315:17EDGAR2Form 8-K - Current report
27/11/202315:15GLOBEAnaptys Expands Immune Cell Modulator Pipeline with..
07/11/202315:15GLOBEAnaptys Named a BioSpace 2024 Best Places to Work Winner
02/11/202315:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202315:18EDGAR2Form 8-K - Current report
02/11/202315:15GLOBEAnaptys Announces Third Quarter 2023 Financial Results and..
01/11/202308:15GLOBEAnaptys Announces Participation in November Investor..
25/10/202315:43EDGAR2Form 8-K - Current report
11/10/202308:15GLOBEAnaptys to Present Phase 1 Data on ANB032, its BTLA Agonist..
10/10/202308:01EDGAR2Form 8-K - Current report
09/10/202307:43DJNAnaptys Sees Positive Trial Results for Imsidolimad..
09/10/202307:15GLOBEAnaptys to Provide Overview of Rosnilimab, a PD-1 Agonist,..
09/10/202307:00GLOBEAnaptys Announces Positive Top-Line Phase 3 Clinical Trial..
18/9/202317:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/9/202317:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/9/202317:09EDGAR2Form 3 - Initial statement of beneficial ownership of..
18/9/202315:18EDGAR2Form 8-K - Current report
18/9/202315:15GLOBEAnaptysBio Announces Appointment of John Orwin as Chairman..
12/9/202308:15GLOBEAnaptysBio to Present at the Stifel 2023 Immunology and..
07/8/202315:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202315:18EDGAR2Form 8-K - Current report
07/8/202315:15GLOBEAnaptysBio Announces Second Quarter 2023 Financial..
31/7/202313:27DJNAnaptysBio Shares Rise 11% After Jemperli Plus Chemotherapy..
31/7/202312:34GLOBEAnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI..
30/5/202315:15GLOBEAnaptysBio Announces Participation in Upcoming Investor..
11/5/202315:15GLOBEAnaptysBio Announces First Quarter 2023 Financial Results..

Su Consulta Reciente

Delayed Upgrade Clock